Alkermes plc. Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Alkermes plc. (ALKS) reported Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest of -$26.54 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-10-27.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments · last filed 2021-10-27
- Alkermes plc. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for the quarter ending 2021-09-30 was -$26.54M, a 1310.54% decline year-over-year.
- Alkermes plc. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for the quarter ending 2021-06-30 was $5.66M.
- Alkermes plc. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for the quarter ending 2021-03-31 was -$18.65M.
- Alkermes plc. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for the quarter ending 2020-12-31 was -$41.65M.
- Alkermes plc. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for fiscal 2020 was -$96.54M.
- Alkermes plc. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for fiscal 2019 was -$197.06M.
- Alkermes plc. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for fiscal 2018 was -$126.97M.
- Alkermes plc. income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest for fiscal 2017 was -$143.27M.
| Period end | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2021-09-30 | -$26.54M 10-Q · filed 2021-10-27 | -$20.88M derived: sum of 2 quarters · filed 2021-10-27 | -$39.53M 10-Q · filed 2021-10-27 | -$81.18M derived: sum of 4 quarters · filed 2021-10-27 |
| 2021-06-30 | $5.66M 10-Q · filed 2021-07-28 | -$13.00M 10-Q · filed 2021-07-28 | -$54.64M derived: sum of 3 quarters · filed 2021-07-28 | -$52.45M derived: sum of 4 quarters · filed 2021-10-27 |
| 2021-03-31 | -$18.65M 10-Q · filed 2021-04-28 | -$60.30M derived: sum of 2 quarters · filed 2021-04-28 | -$58.11M derived: sum of 3 quarters · filed 2021-10-27 | -$83.86M derived: sum of 4 quarters · filed 2021-10-27 |
| 2020-12-31 | -$41.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$39.45M derived: sum of 2 quarters · filed 2021-10-27 | -$65.21M derived: sum of 3 quarters · filed 2021-10-27 | -$96.54M 10-K · filed 2021-02-11 |
| 2020-09-30 | $2.19M 10-Q · filed 2021-10-27 | -$23.57M derived: sum of 2 quarters · filed 2021-10-27 | -$54.89M 10-Q · filed 2021-10-27 | -$57.45M derived: sum of 4 quarters · filed 2021-10-27 |
| 2020-06-30 | -$25.76M 10-Q · filed 2021-07-28 | -$57.08M 10-Q · filed 2021-07-28 | -$59.64M derived: sum of 3 quarters · filed 2021-07-28 | -$113.50M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | -$31.32M 10-Q · filed 2021-04-28 | -$33.88M derived: sum of 2 quarters · filed 2021-04-28 | -$87.74M derived: sum of 3 quarters · filed 2021-04-28 | -$128.13M derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | -$2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$56.42M derived: sum of 2 quarters · filed 2021-02-11 | -$96.80M derived: sum of 3 quarters · filed 2021-02-11 | -$197.06M 10-K · filed 2021-02-11 |
| 2019-09-30 | -$53.86M 10-Q · filed 2019-10-23 | -$94.25M derived: sum of 2 quarters · filed 2019-10-23 | -$194.50M 10-Q · filed 2019-10-23 | -$196.19M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | -$40.39M 10-Q · filed 2019-07-25 | -$140.64M 10-Q · filed 2019-07-25 | -$142.33M derived: sum of 3 quarters · filed 2021-02-11 | -$176.16M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | -$100.25M 10-Q · filed 2019-04-25 | -$101.94M derived: sum of 2 quarters · filed 2021-02-11 | -$135.78M derived: sum of 3 quarters · filed 2021-02-11 | -$160.22M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$35.52M derived: sum of 2 quarters · filed 2021-02-11 | -$59.97M derived: sum of 3 quarters · filed 2021-02-11 | -$126.97M 10-K · filed 2021-02-11 |
| 2018-09-30 | -$33.83M 10-Q · filed 2019-10-23 | -$58.28M derived: sum of 2 quarters · filed 2019-10-23 | -$125.28M 10-Q · filed 2019-10-23 | -$114.49M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | -$24.45M 10-Q · filed 2019-07-25 | -$91.44M 10-Q · filed 2019-07-25 | -$80.66M derived: sum of 3 quarters · filed 2020-02-13 | -$116.45M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | -$67.00M 10-Q · filed 2019-04-25 | -$56.21M derived: sum of 2 quarters · filed 2020-02-13 | -$92.00M derived: sum of 3 quarters · filed 2020-02-13 | -$137.68M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $10.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$25.00M derived: sum of 2 quarters · filed 2020-02-13 | -$70.68M derived: sum of 3 quarters · filed 2020-02-13 | -$143.27M 10-K · filed 2020-02-13 |
| 2017-09-30 | -$35.79M 10-Q · filed 2018-10-23 | -$81.47M derived: sum of 2 quarters · filed 2018-10-23 | -$154.06M 10-Q · filed 2018-10-23 | -$178.37M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-06-30 | -$45.68M 10-Q · filed 2018-07-26 | -$118.27M 10-Q · filed 2018-07-26 | -$142.58M derived: sum of 3 quarters · filed 2019-02-15 | -$207.93M derived: sum of 4 quarters · filed 2019-02-15 |
| 2017-03-31 | -$72.59M 10-Q · filed 2018-04-26 | -$96.90M derived: sum of 2 quarters · filed 2019-02-15 | -$162.25M derived: sum of 3 quarters · filed 2019-02-15 | -$209.96M derived: sum of 4 quarters · filed 2019-02-15 |
| 2016-12-31 | -$24.31M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-15 | -$89.66M derived: sum of 2 quarters · filed 2019-02-15 | -$137.37M derived: sum of 3 quarters · filed 2019-02-15 | -$214.39M 10-K · filed 2019-02-15 |
| 2016-09-30 | -$65.34M 10-Q · filed 2017-10-26 | -$113.06M derived: sum of 2 quarters · filed 2017-10-26 | -$190.07M 10-Q · filed 2017-10-26 | -$262.87M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | -$47.71M 10-Q · filed 2017-07-27 | -$124.73M 10-Q · filed 2017-07-27 | -$197.53M derived: sum of 3 quarters · filed 2018-02-16 | -$275.55M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | -$77.02M 10-Q · filed 2017-04-27 | -$149.81M derived: sum of 2 quarters · filed 2018-02-16 | -$227.83M derived: sum of 3 quarters · filed 2018-02-16 | -$270.88M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | -$72.79M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | -$150.81M derived: sum of 2 quarters · filed 2018-02-16 | -$193.86M derived: sum of 3 quarters · filed 2018-02-16 | -$224.00M 10-K · filed 2018-02-16 |
| 2015-09-30 | -$78.02M 10-Q · filed 2016-11-02 | -$121.06M derived: sum of 2 quarters · filed 2016-11-02 | -$151.21M 10-Q · filed 2016-11-02 | -$110.43M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | -$43.05M 10-Q · filed 2016-07-28 | -$73.19M 10-Q · filed 2016-07-28 | -$32.41M derived: sum of 3 quarters · filed 2017-02-17 | -$68.84M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$30.15M 10-Q · filed 2016-04-28 | $10.63M derived: sum of 2 quarters · filed 2017-02-17 | -$25.80M derived: sum of 3 quarters · filed 2017-02-17 | -$23.59M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $40.78M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $4.35M derived: sum of 2 quarters · filed 2017-02-17 | $6.56M derived: sum of 3 quarters · filed 2017-02-17 | -$14.03M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$36.43M 10-Q · filed 2015-10-29 | -$34.22M derived: sum of 2 quarters · filed 2015-10-29 | -$54.81M 10-Q · filed 2015-10-29 | -$51.94M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $2.21M 10-Q · filed 2015-07-30 | -$18.38M 10-Q · filed 2015-07-30 | -$15.50M derived: sum of 3 quarters · filed 2016-02-25 | -$23.03M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | -$20.59M 10-Q · filed 2015-04-30 | -$17.71M derived: sum of 2 quarters · filed 2016-02-25 | -$25.24M derived: sum of 3 quarters · filed 2016-02-25 | -$15.19M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $2.87M derived: 10-K 9 month − 10-Q 6 month · filed 2016-02-25 | -$4.66M derived: sum of 2 quarters · filed 2016-02-25 | $5.40M 10-K · filed 2016-02-25 | $13.26M 10-K · filed 2016-02-25 |
| 2013-09-30 | -$7.53M 10-Q · filed 2014-10-29 | $2.52M 10-Q · filed 2013-10-31 | $10.39M 10-Q · filed 2014-10-29 | $31.05M derived: sum of 4 quarters · filed 2014-10-29 |
| 2013-06-30 | $10.05M 10-Q · filed 2014-07-31 | $17.92M 10-Q · filed 2014-07-31 | $38.58M derived: sum of 3 quarters · filed 2014-07-31 | $22.30M derived: sum of 4 quarters · filed 2014-07-31 |
| 2013-03-31 | $7.87M 10-Q · filed 2014-04-30 | $28.53M derived: sum of 2 quarters · filed 2014-04-30 | $12.24M derived: sum of 3 quarters · filed 2014-04-30 | $35.44M 10-K · filed 2015-02-24 |
| 2012-12-31 | $20.66M 10-Q · filed 2013-01-31 | $4.38M derived: sum of 2 quarters · filed 2013-10-31 | $27.57M 10-K · filed 2015-02-24 | -$40.19M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-09-30 | -$16.29M 10-Q · filed 2013-10-31 | $6.91M 10-Q · filed 2013-10-31 | -$60.85M derived: sum of 3 quarters · filed 2014-02-27 | -$75.58M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | $23.20M 10-Q · filed 2013-07-25 | -$44.57M derived: sum of 2 quarters · filed 2014-02-27 | -$59.30M derived: sum of 3 quarters · filed 2014-02-27 | -$77.90M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | -$67.77M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | -$82.50M derived: sum of 2 quarters · filed 2014-02-27 | -$101.10M derived: sum of 3 quarters · filed 2014-02-27 | -$114.39M 10-KT · filed 2014-02-27 |
| 2011-12-31 | -$14.73M 10-Q · filed 2013-01-31 | -$33.34M derived: sum of 2 quarters · filed 2013-01-31 | -$46.63M 10-Q · filed 2013-01-31 | -$59.70M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-09-30 | -$18.61M 10-Q · filed 2012-11-01 | -$31.90M 10-Q · filed 2012-11-01 | -$44.97M derived: sum of 3 quarters · filed 2013-05-23 | -$56.31M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-06-30 | -$13.29M 10-Q · filed 2012-07-26 | -$26.36M derived: sum of 2 quarters · filed 2013-05-23 | -$37.71M derived: sum of 3 quarters · filed 2013-05-23 | -$46.32M derived: sum of 4 quarters · filed 2013-05-23 |
| 2011-03-31 | -$13.07M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | -$24.41M derived: sum of 2 quarters · filed 2013-05-23 | -$33.02M derived: sum of 3 quarters · filed 2013-05-23 | -$46.49M 10-K · filed 2013-05-23 |
| 2010-12-31 | -$11.34M 10-Q · filed 2012-02-02 | -$19.95M derived: sum of 2 quarters · filed 2012-02-02 | -$33.42M 10-Q · filed 2012-02-02 | |
| 2010-09-30 | -$8.61M 10-Q · filed 2011-11-03 | -$22.08M 10-Q · filed 2011-11-03 | ||
| 2010-03-31 | -$44.70M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |